WCLC 2026 IMpower030: Atezolizumab Misses Primary Endpoint in NSCLC Perioperative atezolizumab nearly doubles median event-free survival in resectable non-small cell lung cancer, but the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results